Pediatrix Medical Initiated at Outperform by Macquarie
Pediatrix Medical Group Analyst Ratings
Macquarie Upgrades Pediatrix Medical(MD.US) to Buy Rating, Cuts Target Price to $18
Whit Mayo Maintains Hold Rating on Pediatrix Medical Group Amid Mixed Growth Signals and Policy Concerns
Mizuho Securities Maintains Pediatrix Medical(MD.US) With Hold Rating, Announces Target Price $15
Pediatrix Medical Group Analyst Ratings
Jefferies Maintains Pediatrix Medical(MD.US) With Buy Rating, Raises Target Price to $18
Jefferies Reaffirms Their Buy Rating on Pediatrix Medical Group (MD)
Cautious Hold Rating for Pediatrix Medical Group Amid Uncertain Long-Term Growth Prospects
Pediatrix Medical Is Maintained at Hold by Deutsche Bank
Truist Financial Maintains Pediatrix Medical(MD.US) With Hold Rating, Raises Target Price to $16
Mizuho Securities Maintains Pediatrix Medical(MD.US) With Hold Rating
Pediatrix Medical Group Analyst Ratings
Truist Financial Maintains Pediatrix Medical(MD.US) With Hold Rating, Raises Target Price to $13
Jefferies Initiates Pediatrix Medical(MD.US) With Buy Rating, Announces Target Price $14
Buy Rating for Pediatrix Medical Group: Undervalued Stock With Strong Growth and Free Cash Flow Potential
Pediatrix Medical Group Analyst Ratings
Truist Financial Maintains Pediatrix Medical(MD.US) With Hold Rating, Announces Target Price $10
Truist Adjusts Price Target on Pediatrix Medical Group to $10 From $8, Maintains Hold Rating
Pediatrix Medical Group: Cautious Hold Rating Amidst Financial Growth and Restructuring